Lichenoid eruption occurring during chronic hepatitis C treatment with interferon-alpha 2-b plus ribavirin

Öz

Approximately half of the chronic hepatitis C virus infection patients might develop at least one extrahepatic manifestation during the course of the disease. Lichen planus is in group B in accordance with its relation with hepatitis C virus infection, meaning that the prevalence of this disorder is higher than in controls. On the other hand, lichenoid eruptions may arise as an adverse reaction of interferon therapy in chronic hepatitis C virus infection. Our patient had hepatitis C virus infection and developed lichenoid eruptions during the 9th month of interferon plus ribavirin treatment

Anahtar Kelimeler

• Hepatitis C, lichen planus, extrahepatic manifestations

İnterferon alfa 2-b ve ribavirin ile tedavi edilen kronik hepatit C’li hastada geliflen likenoid döküntüler

Öz

Kronik hepatit C'li hastaların yaklaşık yarısında hastalık seyri esnasında en az bir karaciğer dışı bulgu ortaya çıkar. Liken planusun hepatit C ile ilişkisi grup B olarak tanımlanır ki bunun anlamı kontrollere göre daha yüksek sıklıkda görülmekte olduğudur. Bunun yanında likenoid döküntüler kronik hepatit C tedavisine bağlı gelişen bir yan etki olarak da karşımıza çıkabilir. Bizim vakamız interferon 2-b+ribavirin tedavisinin 9. ayında likenoid döküntüleri ortaya çıkan bir hastadır.

Anahtar Kelimeler

• Hepatit C, lichen planus, ekstrahepatik bulgular

Kaynakça

1. Hadziyannis SJ. The spectrum of extrahepatic manifestations in hepatitis C virus infection. J Viral Hepat 1997;4:9-28.
2. Sène D, Saadoun D, Limal N, et al. Update in hepatitis C virus associated extrahepatic manifestations. Rev Med Interne 2007;28: 388-93.
3. Cacoub P, Renou C, Rosenthal E, et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C. Medicine (Baltimore) 2000;79:47-56.
4. Nagao Y, Sata M. Hepatitis C virus and lichen planus. J Gastroenterol Hepatol 2004;19:1101-13.
5. Thornhill MH. Immune mechanisms in oral lichen planus. Acta Odontol Scand 2001;59:174-7.
6. Kirtak N, Inalöz HS, Ozgöztasi, Erba¤ci Z. The prevalence of hepatitis C virus infection in patients with lichen planus in Gaziantep region of Turkey. Eur J Epidemiol 2000;16:1159-61.
7. Nagao Y, Sata M, Abe K, et al. Immunological evaluation in oral lichen planus with chronic hepatitis C. J Gastroenterol 1997;32:324-9.
8. Femiano F, Scully C. Functions of the cytokines in relation oral lichen planus-hepatitis C. Med Oral Patol Oral Cir Bucal 2005;10 (Suppl 1):E40-4.

9. Doutre MS, Beylot C, Couzigou P, et al. Lichen planus and virus C hepatitis: disappearance of the lichen under interferon alfa therapy. Dermatology 1992;184:229.
10. Boccia S, Gamberini S, Dalla Libera M, et al. Lichen planus and interferon therapy for hepatitis C. Gastroenterology 1993;105:1921-2.
11. Barreca T, Corsini G, Franceschini R, et al. Lichen planus induced by interferon-alpha-2a therapy for chronic active hepatitis C. Eur J Gastroenterol Hepatol 1995;7:367-8.
12. Nagao Y, Sata M, Ide T, et al. Development and exacerbation of oral lichen planus during and after interferon therapy for hepatitis C. Eur J Clin Invest 1996;26:1171-4.
13. Schlesinger TE, Camisa C, Gay JD, et al. Oral erosive lichen planus with epidermolytic hyperkeratosis during interferon alfa-2b therapy for chronic hepatitis C virus infection. J Am Acad Dermatol 1997;36:1023-5.
14. Dalekos GN, Christodoulou D, Kistis KG, et al. A prospective evaluation of dermatological side-effects during alpha-interferon therapy for chronic viral hepatitis. Eur J Gastroenterol Hepatol 1998; 10:933-9.
15. Protzer U, Ochsendorf FR, Leopolder-Ochsendorf A, Holtermüller KH. Exacerbation of lichen planus during interferon alfa-2a therapy for chronic active hepatitis C. Gastroenterology 1993;104:903-5.
16. Harden D, Skelton H, Smith KJ. Lichen planus associated with hepatitis C virus: no viral transcripts are found in the lichen planus, and effective therapy for hepatitis C virus does not clear lichen planus. J Am Acad Dermatol 2003;49:847-52.
17. Imhof M, Popal H, Lee JH, et al. Prevalence of hepatitis C virus antibodies and evaluation of hepatitis C virus genotypes in patients with lichen planus. Dermatology 1997;195:1-5.
18. Lodi G, Carrozzo M, Hallett R, et al. HCV genotypes in Italian patients with HCV-related oral lichen planus. J Oral Pathol Med 1997;26:381-4.
19. Sánchez-Pérez J, Moreno-Otero R, Borque MJ, et al. Lichen planus and hepatitis C virus infection: a clinical and virologic study. Acta Derm Venereol 1998;78:305-6.
20. Chuang TY, Stitle L, Brashear R, Lewis C. Hepatitis C virus and lichen planus: a case-control study of 340 patients. J Am Acad Dermatol 1999;41:787-9.
21. Ingafou M, Porter SR, Scully C, Teo CG. No evidence of HCV infection or liver disease in British patients with oral lichen planus. Int J Oral Maxillofac Surg 1998;27:65-6.
22. Tucker SC, Coulson IH. Lichen planus is not associated with hepatitis C virus infection in patients from north west England. Acta Derm Venereol 1999;79:378-9.
23. Guijarro Guijarro B, López Sánchez AF, Hernández Vallejo G. Presence of lichen planus during a course of interferon alpha-2a therapy for a viral chronic C hepatitis. Med Oral 2001;6:358-63.
24. Areias J, Velho GC, Cerqueira R, et al. Lichen planus and chronic hepatitis C: exacerbation of the lichen under interferon-alpha-2a therapy. Eur J Gastroenterol Hepatol 1996;8:825-8.